NovoCure Ltd stock (JE00B6T5S470): shares jump after double-digit move puts focus on valuation
05.06.2026 - 22:21:41 | ad-hoc-news.de
NovoCure Ltd, the Jersey-headquartered oncology device company listed on Nasdaq under the ticker NVCR, has attracted renewed investor attention this week after a pronounced price move in the United States. According to GuruFocus, the stock closed at USD 17.99 on 06/04/2026, up 11.4% on the day and near the upper end of its recent trading range, highlighting heightened volatility in the name and drawing focus back to its valuation profile as a mid-cap medical device player in the US market.GuruFocus as of 06/04/2026
The stock traded at USD 17.99 on 06/04/2026 on Nasdaq, according to GuruFocus, which also reported that NovoCure carried a market capitalization of roughly USD 2.08 billion at that time, placing it firmly in the mid-cap segment of the US-listed medical device universe and underscoring its relevance for investors tracking innovative oncology technologies.WallStreetZen as of 06/04/2026
As of: 05.06.2026
By the editorial team - specialized in equity coverage.
At a glance
- Name: NVCR
- Sector/industry: Medical devices / oncology therapeutics
- Headquarters/country: Saint Helier, Jersey, United Kingdom
- Core markets: United States, Europe, Asia-Pacific
- Key revenue drivers: Tumor Treating Fields therapies for solid tumors, including glioblastoma and other hard-to-treat cancers
- Home exchange/listing venue: Nasdaq (NVCR)
- Trading currency: USD
NovoCure Ltd: core business model
NovoCure Ltd develops and commercializes Tumor Treating Fields-based medical device therapies for solid tumors, generating revenue primarily from the sale and ongoing use of its cancer treatment systems by patients and healthcare providers in key oncology markets worldwide.
Valuation metrics and multiples for NovoCure Ltd
The recent price movement has put NovoCure's valuation back in focus for US investors following the 11.4% single-day gain to USD 17.99 on 06/04/2026, with GuruFocus highlighting that the stock was then trading at a modest discount to its proprietary fair value estimate. GuruFocus reported on 06/04/2026 that its GF Value model assigned NovoCure a fair value of USD 18.64 per share, implying the stock was about 3.5% below this level at the USD 17.99 closing price, a gap the service characterized as indicating undervaluation at that time.GuruFocus as of 06/04/2026
Alongside the fair value comparison, GuruFocus also pointed out on 06/04/2026 that NovoCure carried a GF Score of 70 out of 100, a composite metric that combines profitability, growth, financial strength, momentum, and valuation factors to benchmark the company against peers in the medical technology space, which may be used by some investors to contextualize its risk-return profile within the broader healthcare sector.GuruFocus as of 06/04/2026
Read more
Additional news and developments on the stock can be explored via the linked overview pages.
Sentiment and reactions on NovoCure Ltd
The sharp move in NovoCure's share price and the discussion around its valuation metrics have prompted active debate among investors on social and video platforms.
Conclusion
NovoCure Ltd's double-digit percentage gain to USD 17.99 on Nasdaq on 06/04/2026 has shifted market attention back to the stock, spotlighting both its volatility and its status as a mid-cap medical device name in the United States. With GuruFocus estimating a fair value of USD 18.64 per share and assigning a GF Score of 70 out of 100 as of 06/04/2026, valuation and quality metrics are likely to remain central to how investors frame the risk and opportunity in the shares in the near term.
Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.
